Clinical trials: Cancer of the Esophagus
Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
This phase I trial identifies the best dose, possible benefits and/or side effects of BAY 1895344 in combination with chemotherapy in treating patients with solid tumors or urothelial cancer that has spread to other places in the…
- Conditions
- Advanced Bile Duct Carcinoma, Advanced Breast Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma
- Trial name
- NCT04491942
- Testing
- Cisplatin, Elimusertib, Gemcitabine Hydrochloride
- Where
- 8 sites in United States, Canada
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma
Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
This phase II trial studies how well pembrolizumab and palliative radiation therapy works in treating patients with esophagus, stomach, or gastroesophageal junction cancer that has spread to other parts of the body.
- Conditions
- Gastric Adenocarcinoma, Gastric Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Stomach
- Trial name
- NCT02830594
- Testing
- External Beam Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Non Small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT03551951
- Testing
- Test for circulating tumor cells, DNA alterations
- Where
- United States
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Esophageal Squamous Cell Carcinoma, Dysplasia
Efficacy of Endoscopy Screening on Esophageal Cancer in China (ESECC)
To evaluate the efficacy of endoscopic screening on esophageal cancer (EC) and determine the most cost-effective strategy of endoscopic screening in high risk population in China, 668 villages of Hua county, a high risk area of…
- Trial name
- ESECC (NCT01688908)
- Testing
- Endoscopic Screening
- Where
- China
- Volunteers
- 33,948 people, healthy volunteers welcome
- Sponsor
- Peking University
Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III
HEARTS Trial for Thoracic Cancers
The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the…
- Conditions
- Non-Small Cell Lung Cancer (Stage III), Esophageal Cancer Stage I-III, Esophagogastric Cancer Stage I-III, Thymoma and Thymic Carcinoma Stage II-III
- Trial name
- NCT07132918
- Testing
- MRgART, LINAC
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC)
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with…
- Conditions
- Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), Melanoma, Cervical Cancer
- Trial name
- ARC-12 (NCT04772989)
- Testing
- AB308, Zimberelimab
- Where
- 22 sites in United States, Poland and 1 more
- Volunteers
- 94 people
- Sponsor
- Arcus Biosciences, Inc.
Esophageal Cancer
A Phase II Clinical Study to Evaluate HLX43 in Patients With Recurrent/Metastatic ESCC Failed or Intolerance to Standard Therapy
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent/Metastatic Esophageal Squamous Cell Carcinomar (ESCC) Failed or…
- Trial name
- NCT06769113
- Testing
- HLX43
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Shanghai Henlius Biotech
Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
The purpose of this Phase I study is to determine the recommended phase 2 dose (RP2D) and safety profile of NBTXR3 activated by radiation therapy with concurrent chemotherapy for the treatment of patients with esophageal…
- Conditions
- Cervical Esophagus Adenocarcinoma, Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8
- Trial name
- NCT04615013
- Testing
- Capecitabine, Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Superficial Esophageal Neoplasia
Narrow Band Imaging (NBI) Against Lugol for Squamous Esophageal Cancer
This study aimed to compare Narrow Band Imaging (NBI) against Lugol chromoendoscopy for diagnosis of early esophageal cancers among high risk patients.
- Trial name
- NCT02002559
- Volunteers
- 180 people
- Sponsor
- Chinese University of Hong Kong
Esophageal Squamous Cell Carcinoma
SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma
This study was designed to predict the toxicity and efficacy of Simultaneous Integrated Boost Intensity-modulated Chemoradiotherapy in Upper Thoracic I-IVA Esophageal Squamous Cell Carcinoma.
- Trial name
- NCT04115618
- Testing
- Simultaneous integrated boost intensity-modulated chemoradiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Fudan University
Esophageal Cancer
Endoesophageal Brachytherapy for Patients With Esophageal Cancer
Depending upon the cancer stage, esophageal cancer can be treated with surgery, chemotherapy, radiation therapy, or a combination of these modalities.
- Trial name
- NCT03335813
- Testing
- Endoesophageal Brachytherapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Case Comprehensive Cancer Center
Esophageal Cancer
Cetuximab/Paclitaxel/Cisplatin Concurrent Chemoradiotherapy Followed by Esophagectomy for Loco-regional Esophageal Cancer
We hypothesize that the addition of cetuximab to twice weekly paclitaxel/cisplatin concurrent chemoradiotherapy (TP-CCRT) as the adjunctive therapy before esophagectomy or as a definitive CRT would improve the therapeutic…
- Trial name
- NCT01034189
- Testing
- Cetuximab, Paclitaxel, Cisplatin
- Where
- Taiwan
- Volunteers
- 62 people
- Sponsor
- National Taiwan University Hospital
Esophageal Cancer, Adenocarcinoma of the Esophagus
Total Neoadjuvant Therapy for Lymph Node-positive Adenocarcinoma of the OESophagus and Oesophagogastric Junction
Both neoadjuvant chemoradiotherapy (CROSS) and neoadjuvant chemotherapy (FLOT) have demonstrated overall survival benefit over surgery alone in esophageal and esophagogastric junction (EGJ) cancer.
- Trial name
- TNT-OES-2 (NCT06161818)
- Testing
- FLOT-CROSS or CROSS-FLOT
- Where
- 10 sites in Netherlands
- Volunteers
- 216 people
- Sponsor
- Erasmus Medical Center
CNS Brain Metastases, Head and Neck Cancer
Pilot Study of (61)CuATSM-PET Imaging in Cancer Patients
Hypoxia is a key factor in malignant progression of a neoplasm. It is our aim to explore the basis for quantitative in vivo tumor imaging by Cu-61 diacetyl-bis(N4-methylthiosemicarbazone)PET imaging as a surrogate of tissue…
- Conditions
- CNS Brain Metastases, Head and Neck Cancer, Lung Cancer, Prostate Cancer
- Trial name
- NCT00585117
- Testing
- PET-imaging with CuATSM, PET Imaging, PET CuATSM
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Wisconsin, Madison
Esophageal Squamous Cell Carcinoma, Pathological Complete Response
Predicting Pathological Complete Response in Esophageal Squamous Cell Carcinoma Using a Multimodal Model Integrating Clinical, Radiomics, and Deep Learning Features
This multicenter, retrospective cohort study reviews the medical records and CT scans of adults with esophageal squamous cell carcinoma (ESCC) who received neoadjuvant immunotherapy plus chemotherapy before surgery at three…
- Trial name
- pCR-ESCC (NCT07181850)
- Testing
- Standard-of-Care Neoadjuvant Immunochemotherapy (nIT+nCT)
- Where
- China
- Volunteers
- 363 people
- Sponsor
- Nanjing Medical University
Esophageal Squamous Cell Cancer
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as 1st Line Treatment for Esophageal Squamous Cell Cancer
Metastatic esophageal squamous cell carcinomas have poor prognosis and majority of patients resistant to chemotherapy in China. In the investigators phase II clinical trial proceeded before, the combination of paclitaxel with…
- Trial name
- NCT02016274
- Testing
- Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Shen Lin
Mesolthelioma, Esophageal Cancer
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
Background: Recent research has shown that causing an immune response to tumor cells may help slow or stop the growth of tumors.
- Conditions
- Mesolthelioma, Esophageal Cancer, Lung Cancer, Thoracic Sarcomas
- Trial name
- NCT01258868
- Testing
- Celebrex, Tumor cell vaccine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Esophageal Cancer
Gefitinib Combined With Radiotherapy in Elderly Patients With Esophageal Cancer
Elderly patients with esophageal cancer will receive thoracic radiation therapy 54-60Gy over 30 fractions, and concurrent with Gefitinib.
- Trial name
- NCT01291823
- Testing
- gefitinib, Thoracic radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang Cancer Hospital
Esophageal Cancer, Advanced Solid Tumor
Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function
To evaluate the pharmacokinetics and safety of Larotinib in subjects with mild and moderate hepatic function impairment and healthy subjects in a single-center, non-randomized, open, single-dose administration
- Trial name
- NCT05048368
- Testing
- Larotinib
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Endometrial Cancer, Esophageal Cancer
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and MAGE-A4 tumor antigen.
- Conditions
- Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
- Trial name
- NCT04044859
- Testing
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 120 people
- Sponsor
- USWM CT, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.